|Infinity Pharmaceuticals Inc -- USA Stock|| |
USD 1.82 0.12 6.19%
Vice President - Clinical Development
Dr. Joseph Pearlberg, M.D. Ph.D., serves as Vice President Clinical Development of the Company
President Since 2017 Ph.D
Joseph Pearlberg joined Infinity in 2014 and has 25 years of experience in research and medicine. Prior to joining Infinity, Dr. Pearlberg worked at Sanofi from 2010 to 2014 where he held various roles of increasing responsibility within the clinical development organization. Prior to that, Dr. Pearlberg held a postdoctoral fellowship at Harvard Medical School from 2002 to 2010. During his career, he also held various medical and research positions at Dana Farber Cancer Center and Massachusetts General Hospital. Additionally, Dr. Pearlberg was a Genentech Research Fellow from 1997 to 1999. He earned a M.D. from University of California, San Francisco, a Ph.D. in molecular biology from Harvard University and a B.A. from University of Pennsylvania.
The company has return on total asset (ROA)
of (27.38) %
which means that it has lost $27.38 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (73.91) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 6 M in liabilities with Debt to Equity (D/E) ratio of 11.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Infinity Pharmaceuticals Inc has Current Ratio of 5.76 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Infinity Pharmaceuticals, Inc., a drug discovery and development company, discovers, develops, and delivers medicines to patients with difficulttotreat diseases. Infinity Pharmaceuticals Inc (INFI) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 48 people. Infinity Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.